The AstraZeneca Covid-19 vaccine is definitely not attracting the same interest as the Pfizer/BioNTech vaccine at the European Commission (see EUROPE B12701A9). The institution did not activate the option to purchase the additional 100 million doses it could have benefited from under the contract signed with the Swedish-British pharmaceutical group.
“The deadline for activating the option has passed”, a Commission spokesperson told the press on Thursday 22 April.
This deadline has not...